Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 4.62% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 4.62% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 3.03% from the prior year.
• Total Non-Current Liabilities climbed to $1.3 billion in Q1 2026 per INDV's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.7 billion in Q2 2025 and bottomed at $649.0 million in Q4 2023.
• The 5-year median for Total Non-Current Liabilities is $1.3 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Total Non-Current Liabilities retreated 15.27% in 2022 and soared 98.31% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $699.0 million in 2022, then retreated by 7.15% to $649.0 million in 2023, then surged by 98.31% to $1.3 billion in 2024, then retreated by 3.03% to $1.2 billion in 2025, then grew by 4.17% to $1.3 billion in 2026.
• Per Business Quant, the three latest INDV Total Non-Current Liabilities figures stand at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025).